Mark Agulnik

10.1k total citations · 1 hit paper
165 papers, 4.2k citations indexed

About

Mark Agulnik is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Pathology and Forensic Medicine. According to data from OpenAlex, Mark Agulnik has authored 165 papers receiving a total of 4.2k indexed citations (citations by other indexed papers that have themselves been cited), including 96 papers in Pulmonary and Respiratory Medicine, 94 papers in Oncology and 34 papers in Pathology and Forensic Medicine. Recurrent topics in Mark Agulnik's work include Sarcoma Diagnosis and Treatment (70 papers), Vascular Tumors and Angiosarcomas (30 papers) and Head and Neck Cancer Studies (24 papers). Mark Agulnik is often cited by papers focused on Sarcoma Diagnosis and Treatment (70 papers), Vascular Tumors and Angiosarcomas (30 papers) and Head and Neck Cancer Studies (24 papers). Mark Agulnik collaborates with scholars based in United States, United Kingdom and Canada. Mark Agulnik's co-authors include Lillian L. Siu, Joel B. Epstein, Scott H. Okuno, Gregory R. Pond, Ari J. Rosenberg, Margaret von Mehren, Jessica Lee Yarber, Bruce Brockstein, Brian A. Van Tine and Andrew M. Evens and has published in prestigious journals such as The Lancet, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

In The Last Decade

Mark Agulnik

158 papers receiving 4.2k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Olaratumab and doxorubicin versus doxorubicin alone for treatment of soft-tissue sarcoma: an open-label phase 1b and randomised phase 2 trial

2016 436 citations William D. Tap, Robin L. Jones et al. profile →

Peers

Countries citing papers authored by Mark Agulnik

Since Specialization

Citations

This map shows the geographic impact of Mark Agulnik's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mark Agulnik with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mark Agulnik more than expected).

Fields of papers citing papers by Mark Agulnik

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mark Agulnik. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mark Agulnik. The network helps show where Mark Agulnik may publish in the future.

Co-authorship network of co-authors of Mark Agulnik

This figure shows the co-authorship network connecting the top 25 collaborators of Mark Agulnik. A scholar is included among the top collaborators of Mark Agulnik based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mark Agulnik. Mark Agulnik is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Botensilimab (Fc-enhanced anti–cytotoxic lymphocyte-association protein-4 antibody) Plus Balstilimab (anti–PD-1 antibody) in Patients With Relapsed/Refractory Metastatic Sarcomas 2025 ·Journal of Clinical Oncology ·Breelyn A. Wilky, Gary K. Schwartz, Michael S. Gordon, Anthony B. El-Khoueiry, Andrea J. Bullock, Brian S. Henick, Mark Agulnik, Arun S. Singh, Daruka Mahadevan, Justin Stebbing, Chloé Delépine, Dhan Chand, (unknown), (unknown), Benny Johnson, Joseph E. Grossman, Steven O’Day, Jonathan C. Trent, Robin L. Jones, Apostolia M. Tsimberidou	9
2	Peak part 1 summary: A phase 3, randomized, open-label multicenter clinical study of bezuclastinib (CGT9486) and sunitinib combination versus sunitinib in patients with gastrointestinal stromal tumors (GIST). 2024 ·Journal of Clinical Oncology ·Andrew J. Wagner, Jonathan C. Trent, Steven Attia, Mark Agulnik, Breelyn A. Wilky, William D. Tap, Margaret von Mehren, Elizabeth J. Davis, (unknown), Nisha Shah, (unknown), Julia Lawrence, Lei Sun, Neeta Somaiah	1
3	Abstract CT066: Phase 1 study of MDM2 antagonist ASTX295 in patients with solid tumors with wild-type TP53 2024 ·Cancer Research ·Ecaterina E. Dumbrava, Fábio M. Iwamoto, Mark Agulnik, Mohammed Milhem, Anthony W. Tolcher, Rashmi Chugh, Michael J. Demeure, Alain C. Mita, (unknown), Mark S. Diamond, Beloo Mirakhur, (unknown), Aram Oganesian, (unknown), Harold Keer, Jason Taylor, Martin Sims, Andrea Biondo, Simone Jueliger, Alexander I. Spira	1
4	Current unmet needs in locally advanced (unresectable) or metastatic dedifferentiated liposarcoma, the relevance of progression-free survival as clinical endpoint, and expectations for future clinical trial design: an international Delphi consensus report 2024 ·ESMO Open ·Patrick Schöffski, Robin L. Jones, Mark Agulnik, Jean‐Yves Blay, A. Chalmers, (unknown), Daniel Pink, Silvia Stacchiotti, (unknown), Bruno Vincenzi, Michael J. Wagner, Robert G. Maki	1
5	Prices and Trends in FDA-Approved Medications for Sarcomas 2024 ·Cancers ·Caleb Hwang, Mark Agulnik, Brian Schulte	1
6	Cabozantinib Plus Ipilimumab/Nivolumab in Patients With Previously Treated Advanced Differentiated Thyroid Cancer 2024 ·The Journal of Clinical Endocrinology & Metabolism ·Bhavana Konda, Eric J. Sherman, Erminia Massarelli, Jorge J. Nieva, Jameel Muzaffar, (unknown), Mabel Ryder, Alan L. Ho, Mark Agulnik, Lai Wei, (unknown), (unknown), (unknown), John Wright, Howard Streicher, William E. Carson, Manisha H. Shah	4
7	Lete-cel in patients with synovial sarcoma or myxoid/round cell liposarcoma: Planned interim analysis of the pivotal IGNYTE-ESO trial. 2024 ·Journal of Clinical Oncology ·Sandra P. D’Angelo, Andrew Furness, Fiona Thistlethwaite, Melissa Burgess, Richard F. Riedel, John B.A.G. Haanen, Jonathan Noujaim, A. Chalmers, Antonio López–Pousa, Rashmi Chugh, Lara E. Davis, Édouard Forcade, Mark Agulnik, Dennis Williams, Mary Woessner, Thomas Faitg, (unknown), Michael J. Nathenson, Elliot Norry, Albiruni Ryan Abdul Razak	9
8	Bioinformatic Analysis of Recurrent Genomic Alterations and Corresponding Pathway Alterations in Ewing Sarcoma 2023 ·Journal of Personalized Medicine ·(unknown), (unknown), Janet Yoon, Mark Agulnik, Warren Chow, Sherri Z. Millis	1
9	SMARCA4/BRG1-deficient Uterine Neoplasm With Hybrid Adenosarcoma and Carcinoma Features: Expanding the Molecular-morphologic Spectrum of SMARCA4-driven Gynecologic Malignancies 2023 ·International Journal of Gynecological Pathology ·Christina Wei, Evita Sadimin, Mark Agulnik, Susan E. Yost, Teri A. Longacre, Oluwole Fadare	1
10	OER‐073: A multicenter phase 2 study evaluating the role of pazopanib in angiosarcoma 2022 ·Cancer ·(unknown), Vinod Ravi, (unknown), Scott M. Schuetze, Sujana Movva, Mark Agulnik, Andrew S. Kraft, Eric D. Tetzlaff, Neeta Somaiah, Margaret von Mehren	12
11	Evolving strategies for management of desmoid tumor 2022 ·Cancer ·Richard F. Riedel, Mark Agulnik	28
12	Randomized Double-Blind Phase II Study of Regorafenib in Patients With Metastatic Osteosarcoma 2019 ·Journal of Clinical Oncology ·Lara E. Davis, Vanessa Bolejack, Christopher W. Ryan, Kristen N. Ganjoo, Elizabeth T. Loggers, Sant P. Chawla, Mark Agulnik, Michael B. Livingston, Damon R. Reed, (unknown), Daniel A. Rushing, Scott H. Okuno, Denise K. Reinke, Richard F. Riedel, Steven Attia, Leo Mascarenhas, Robert G. Maki	174
13	Epithelioid Hemangioendothelioma: Update on Diagnosis and Treatment 2018 ·Current Treatment Options in Oncology ·Ari J. Rosenberg, Mark Agulnik	99
14	Stereotactic radiosurgery for brain metastases from primary head and neck carcinomas: a retrospective analysis 2017 ·Journal of Neuro-Oncology ·(unknown), Jonathan B. Bell, Thomas Kim, Mark Agulnik, James P. Chandler, Bharat B. Mittal, Tim J. Kruser	6
15	Fibroblast Growth Factor Receptor (FGFR) as a Therapeutic Target in Lung and Head and Neck Cancer 2016 ·Young Kwang Chae, Sachin Gopalkrishna Pai, Peng Sun, Ricardo Costa, Maria Matsangou, Mark Agulnik, Francis J. Giles	6
16	Phase II study of MLN8237 (Alisertib) in advanced/metastatic sarcoma 2016 ·Annals of Oncology ·Mark A. Dickson, M. R. Mahoney, William D. Tap, Sandra P. D’Angelo, Mary Louise Keohan, Brian A. Van Tine, Mark Agulnik, Laura E. Horvath, Jayasree S. Nair, Gary K. Schwartz	90
17	Overview and Management of Dermatologic Events Associated with Targeted Therapies for Medullary Thyroid Cancer 2014 ·Thyroid ·Mario E. Lacouture, Kathryn Ciccolini, Richard T. Kloos, Mark Agulnik	28
18	Understanding Rechallenge and Resistance in the Tyrosine Kinase Inhibitor Era 2012 ·American Journal of Clinical Oncology ·Mark Agulnik, Jennifer L. Giel	11
19	Occult Primary 2011 ·Journal of the National Comprehensive Cancer Network ·David S. Ettinger, Mark Agulnik, Justin Cates, Mihaela Cristea, Crystal S. Denlinger, Keith D. Eaton, P. Fidias, David S. Gierada, Jon P. Gockerman, Charles R. Handorf, Renuka Iyer, Renato Lenzi, John E. Phay, Asif Rashid, Leonard B. Saltz, Lawrence N. Shulman, Jeffrey B. Smerage, Gauri R. Varadhachary, Jonathan S. Zager, Weining Zhen	35
20	Salivary Gland Malignancies: The Role for Chemotherapy and Molecular Targeted Agents 2008 ·Seminars in Oncology ·(unknown), Mark Agulnik	41

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact